
Sign up to save your podcasts
Or


We discuss clinical trials using CNTF to treat MacTel Type 2 with Dr. John Pollack, Chief Medical Officer of Neurotech Pharmaceuticals.
By Retina Synthesis4.5
88 ratings
We discuss clinical trials using CNTF to treat MacTel Type 2 with Dr. John Pollack, Chief Medical Officer of Neurotech Pharmaceuticals.

18 Listeners

2,446 Listeners

112,734 Listeners

673 Listeners

56,473 Listeners

594 Listeners

4 Listeners

11 Listeners

52 Listeners

10 Listeners

18 Listeners

1 Listeners

0 Listeners

710 Listeners